NDA 020671/S-024

CBE SUPPLEMENT –
ACKNOWLEDGEMENT/APPROVAL

Novartis Pharmaceuticals Corporation
Attention: Sneha Desai
Global Program Regulatory Manager, Regulatory Affairs
One Health Plaza
East Hanover, NJ 07936

Dear Ms. Desai:[1]

We have received your supplemental new drug application (sNDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA or the Act) in regards to the telephone conference request described below.

We refer to our August 15, 2019, telephone conversation with a representative of Novartis Pharmaceuticals and to your subsequent response received via e-mail confirming our telephone discussion in which we requested that you submit a supplement to add the statement "HYCAMTIN for injection is a cytotoxic drug. Follow applicable handling and disposal procedures," to the Dosage and Administration, Preparation and Intravenous Administration subsection and add section 2.1, Important Safety Information in the Full Prescribing Information: Contents of the package insert as these were inadvertently omitted.

NDA NUMBER: 020671

SUPPLEMENT NUMBER: 24

PRODUCT NAME: Hycamtin (topotecan hydrochloride), for injection, 4 mg

DATE OF SUBMISSION: August 29, 2019

DATE OF RECEIPT: August 29, 2019

This supplemental application, submitted as a Changes Being Effected (CBE) supplement, provides for revisions to the Table of Contents for the DOSAGE AND ADMINISTRATION section, to add the sub-section heading, Important Safety Information (2.1); and, to add the statement *"HYCAMTIN for injection is a cytotoxic drug. Follow applicable handling and disposal procedures,"* in the Dosage and

[1] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

Administration Preparation and Intravenous Administration (2.7) subsection, and minor revisions for consistency with current labeling practices, per our request.

APPROVAL & LABELING

We have completed our review of this supplement application, as amended. It is approved effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[2] Content of labeling must be identical to the enclosed labeling text for the Prescribing Information, with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[3]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

[2] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[3] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the Prescribing Information to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.*[4]
You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.[5] Information and Instructions for completing the form can be found at FDA.gov.[6] For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see FDA.gov.[7]

---

[4] When final, this guidance will represent the FDA's current thinking on this topic. For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

[5] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
[6] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf
[7] http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have questions, call Stacie Woods, Pharm.D., Regulatory Health Project Manager, at 301-796-4803.

Sincerely,

{See appended electronic signature page}

Jeffery Summers, M.D.
Deputy Director for Safety
Division of Oncology Products 2
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JEFFERY L SUMMERS
10/08/2019 10:09:43 AM